CEO-Partner and CEO of Sonata Therapeutics
Volker Herrmann is a Flagship Pioneering CEO-Partner and Chief Executive Officer of Sonata Therapeutics. A veteran pharmaceutical and biotech leader, he brings to Flagship and Sonata, more than 20 years of experience in management, commercial development, business development, marketing, and strategy. Volker was previously the CEO of Inzen Therapeutics, another Flagship founded company, and a predecessor to Sonata. He is a member of the broader Flagship leadership team, where he serves on selected Flagship company boards and provides his experience across the ecosystem.
Previously, Volker was Chief Operating Officer and President at SQZ Biotechnologies. Prior to this role, he was at Pfizer for 17 years, where he held leadership roles for a variety of therapeutic areas, including European Lead CNS/Pain franchise, Global Lead Pain franchise, and Head of Global Strategy, Marketing and Commercial Development for Pfizer’s Vaccine Business Unit. Subsequently, he served as the Chief Commercial Officer for Viamet Pharmaceuticals, where he was responsible for preparing the organization for the launch of their first commercial product as well as streamlining the company’s pipeline. Volker also served as the COO of Selenity Therapeutics.
Volker received his M.D. from Albert-Ludwigs University Freiburg in Germany and an M.B.A. from the University of San Diego, School of Graduate Business.